New directions in pharmacological treatment of acromegaly

Expert Opinion on Investigational Drugs

Volumn 18, Issue 1, 2009, Pages 13-22

  Bollerslev, Jens ^a,c   Fougner, Stine L ^a,c   Berg, Jens P ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Dopamin; Pegvisomant; Pituitary; Somatostatin; Somatotroph adenoma

Indexed keywords

ANGIOPEPTIN; BIM 23A 760; CABERGOLINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HORMONE RECEPTOR BLOCKING AGENT; LANREOTIDE AUTOGEL; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ACROMEGALY; ADD ON THERAPY; ADENOMA; AMINOTRANSFERASE BLOOD LEVEL; AORTA VALVE DISEASE; CALCIFICATION; CLINICAL TRIAL; DATA BASE; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; GROWTH HORMONE SECRETING ADENOMA; HORMONE RELEASE; HUMAN; HYPOPHYSIS; IMMUNOHISTOCHEMISTRY; LIPODYSTROPHY; MACROADENOMA; MEDLINE; PROLACTINOMA; RECEPTOR AFFINITY; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TACHYPHYLAXIS; TRICUSPID VALVE REGURGITATION; TUMOR; TUMOR GROWTH; VALVULAR HEART DISEASE;

ACROMEGALY; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, SOMATOSTATIN; RECEPTORS, SOMATOTROPIN;

EID: 67649361905     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802554357     Document Type: Review

References (110)

1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25(1):102-152 (Pubitemid 38269977)
2. Bush ZM, Vance ML. Management of acromegaly: is there a role for primary medical therapy? Rev Endocr Metab Disord 2008;9(1):83-94
3. Nachtigall L, Delgado A, Swearingen B, et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 2008;93(6):2035-2041
4. Bates PR, Carson MN, Trainer PJ, Wass JA. Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol (Oxf) 2008;68(1):136-142 (Pubitemid 350243493)
5. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87(10):4554-4563
6. Bex M, Abs R, T'Sjoen G, et al. AcroBel - the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 2007;157(4):399-409
7. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 2008;93(8):2984-2990
8. De P, Rees DA, Davies N, et al. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 2003;88(8):3567-3572 (Pubitemid 37034496)
9. Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 1996;45(4):407-413 (Pubitemid 26383417)
10. Biermasz NR, Van DH, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85(12):4596-4602 (Pubitemid 32157639)
11. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998;89(3):353-358 (Pubitemid 28405246)
12. Lissett CA, Peacey SR, Laing I, et al. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 1998;49(5):653-657 (Pubitemid 28529765)
13. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005;152(3):379-387
14. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93(1):61-67
15. Clemmons DR, Chihara K, Freda PU, et al. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003;88(10):4759-4767 (Pubitemid 37357523)
16. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153(6):737-740 (Pubitemid 43020222)
17. Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89(4):1613-1617 (Pubitemid 38507910)
18. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89(6):2789-2796 (Pubitemid 38766367)
19. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89(2):667-674 (Pubitemid 38269875)
20. Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005;90(7):4081-4086 (Pubitemid 41058176)
21. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83(8):2730-2734
22. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159(2):89-95
23. Paisley AN, Trainer PJ. Recent developments in the therapy of acromegaly. Expert Opin Investig Drugs 2006;15(3):251-256 (Pubitemid 43338146)
24. Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 2008;286(1-2):192-198
25. Erfurth EM, Bulow B, Hagmar LE. Is vascular mortality increased in hypopituitarism? Pituitary 2000;3(2):77-81
26. Vik-Mo EO, Oksnes M, Pedersen PH, et al. Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol 2007;157(3):255-263 (Pubitemid 47603528)
27. Losa M, Gioia L, Picozzi P, et al. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 2008;93:2546-2552 (Pubitemid 352008518)
28. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005;90(8):4483-4488 (Pubitemid 41159330)
29. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86(6):2779-2786 (Pubitemid 32545739)
30. Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007;67(2):282-289 (Pubitemid 47076308)
31. Ferone D, De Herder WW, Pivonello R, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 2008;93(4):1412-1417
32. Fougner SL, Borota OC, Berg JP, et al. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 2008;68(3):458-465 (Pubitemid 351257867)
33. Plockinger U, Albrecht S, Mawrin C, et al. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 2008;93(4):1203-1210
34. Freda PU, Katznelson L, Van Der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90(8):4465-4473 (Pubitemid 41159328)
35. Andries M, Glintborg D, Kvistborg A, et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2008;68(3):473-480 (Pubitemid 351257869)
36. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151(3):317-324 (Pubitemid 39307318)
37. Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2004;56(4):471-476 (Pubitemid 38455612)
38. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87(1):99-104 (Pubitemid 34084677)
39. Ivan G, Szigeti-Csucs N, Olah M, et al. Treatment of pituitary tumors: dopamine agonists. Endocrine 2005;28(1):101-110 (Pubitemid 43004807)
40. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83(2):374-378 (Pubitemid 28496509)
41. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356(1):29-38 (Pubitemid 46041751)
42. Lancellotti P, Livadariu E, Markov M, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008;159(1):1-5 (Pubitemid 351969123)
43. Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008;93(9):3348-3356
44. Paisley AN, Trainer P, Drake W. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert Opin Biol Ther 2004;4(3):421-425 (Pubitemid 38352136)
45. Parkinson C, Trainer PJ. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. Growth Horm IGF Res 2000;10(Suppl B):S119-23 (Pubitemid 30637229)
46. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171-1177 (Pubitemid 30211048)
47. Van Der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358(9295):1754-1759 (Pubitemid 33152999)
48. Bonert VS, Kennedy L, Petersenn S, et al. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008;93(9):3515-3518
49. Paisley AN, Hayden K, Ellis A, et al. Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol 2007;156(3):315-319 (Pubitemid 46554499)
50. Orskov H, Frystyk J, Nielsen C, et al. Concomitant, specific determination of growth hormone and pegvisomant in human serum. Growth Horm IGF Res 2007;17(5):431-434 (Pubitemid 47324308)
51. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156(1):75-82 (Pubitemid 46553905)
52. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004;61(2):209-215 (Pubitemid 39093116)
53. Harris PE, D'Souza GA, Good AJ, et al. Treatment with pegvisomant alone compared to combination therapy with pegisomant/octreotide LAR, in acromegaly The Endocrine Society 89th Annual Meeting, Toronta Canada, June 2-5, 2007 . Abstract OR 53-63
54. Feenstra J, De Herder WW, Ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365(9471):1644-1646 (Pubitemid 40693415)
55. Neggers SJ, Van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92(12):4598-4601 (Pubitemid 350223432)
56. Neggers SJ, Van Aken MO, De Herder WW, et al. Significant improvement of quality of life in biochemical controlled acromegalic patients during long-term somatostatin analog treatment by the addition of low-dose weekly pegvisomant. The Endocrine Society 90th annual meeting, San Francisco, June 15-18, 2008: Abstract S-68-74
57. Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003;149(6):521-527 (Pubitemid 38054695)
58. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005;90(10):5627-5631 (Pubitemid 41415468)
59. Ueland T, Ebbesen EN, Thomsen JS, et al. Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly. Eur J Clin Invest 2002;32(2):122-128 (Pubitemid 36232733)
60. Ueland T, Fougner SL, Godang K, et al. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 2006;155(5):709-715 (Pubitemid 44857495)
61. Roelfsema F, Biermasz NR, Pereira AM, Romijn J. Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int J Nanomedicine 2006;1(4):385-398
62. Barlier A, Pellegrini-Bouiller I, Gunz G, et al. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 1999;84(8):2759-2765 (Pubitemid 30642008)
63. Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000;85(2):781-792 (Pubitemid 32273669)
64. Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86(1):140-145 (Pubitemid 32109787)
65. Park C, Yang I, Woo J, et al. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 2004;51(2):227-236 (Pubitemid 38657560)
66. Taboada GF, Luque RM, Neto LV, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008;158(3):295-303
67. Corbetta S, Ballare E, Mantovani G, et al. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 2001;31(3):208-214 (Pubitemid 32275726)
68. Fisher WE, Doran TA, Muscarella P, et al. Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J Natl Cancer Inst 1998;90(4):322-324 (Pubitemid 28182389)
69. Takei M, Suzuki M, Kajiya H, et al. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocr Pathol 2007;18(4):208-216
70. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90(3):1856-1863 (Pubitemid 40464061)
71. Resmini E, Dadati P, Ravetti JL, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007;92(5):1592-1599 (Pubitemid 46997156)
72. Casarini AP, Pinto EM, Jallad RS, et al. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 2006;29(9):826-830 (Pubitemid 44872594)
73. Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 2007;156(1):65-74 (Pubitemid 46553904)
74. Ferrante E, Pellegrini C, Bondioni S, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006;13(3):955-962 (Pubitemid 44767383)
75. Zatelli MC, Piccin D, Tagliati F, et al. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro J Mol Endocrinol 2005;35(2):333-341
76. Bhayana S, Booth GL, Asa SL, et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005;90(11):6290-6295 (Pubitemid 41606558)
77. Ezzat S, Kontogeorgos G, Redelmeier DA, et al. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 1995;133(6):686-690
78. Stefaneanu L, Kovacs K, Thapar K, et al. Octreotide effect on growth hormone and somatostatin subtype 2 receptor mrnas of the human pituitary somatotroph adenomas. Endocr Pathol 2000;11(1):41-48 (Pubitemid 30307943)
79. Obari A, Sano T, Ohyama K, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 2008;19(2):82-91
80. Coons SW, Estrada SI, Gamez R, White WL. Cytokeratin CK 7 and CK 20 expression in pituitary adenomas. Endocr Pathol 2005;16(3):201-210 (Pubitemid 41687191)
81. Yamada S, Aiba T, Sano T, et al. Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 1993;33(1):20-27 (Pubitemid 23204807)
82. Nishioka H, Haraoka J, Akada K. Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas. Clin Endocrinol (Oxf) 2003;59(6):768-772 (Pubitemid 37491582)
83. Sano T, Rong QZ, Kagawa N, Yamada S. Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 2004;32:127-132
84. Qian ZR, Sano T, Yoshimoto K, et al. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 2007;20(12):1269-1277 (Pubitemid 350126852)
85. Asa SL, Digiovanni R, Jiang J, et al. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 2007;67(15):7505-7511 (Pubitemid 47206580)
86. Spada A, Arosio M, Bochicchio D, et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 1990;71(6):1421-1426 (Pubitemid 120032754)
87. Buchfelder M, Fahlbusch R, Merz T, et al. Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes. Pituitary 1999;1(3-4):181-185
88. Freda PU, Chung WK, Matsuoka N, et al. Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. Pituitary 2007;10(3):275-282 (Pubitemid 350055039)
89. Picard C, Silvy M, Gerard C, et al. Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. Int J Cancer 2007;121(6):1245-1252 (Pubitemid 47293791)
90. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008;3:822-840
91. Lorenz K, Lohse MJ, Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 2003;426(6966):574-579 (Pubitemid 37522645)
92. Tulipano G, Stumm R, Pfeiffer M, et al. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004;279(20):21374-21382 (Pubitemid 38656546)
93. Fougner SL, Bollerslev J, Latif F, et al. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Metab 2008;93(4):1211-1216
94. Granovsky AE, Rosner MR. Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res 2008;18(4):452-457
95. Kurosaki M, Saeger W, Abe T, Ludecke DK. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res 2008 (Pubitemid 352008712)
96. Vidal S, Kovacs K, Horvath E, et al. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol 2002;15(11):1205-1212 (Pubitemid 35435139)
97. Masuda A, Shibasaki T, Kim YS, et al. The somatostatin analog octreotide inhibits the secretion of growth hormone (GH)-releasing hormone, thyrotropin, and GH in man. J Clin Endocrinol Metab 1989;69(4):906-909 (Pubitemid 19245875)
98. Hyer SL, Sharp PS, Brooks RA, et al. A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metabolism 1989;38(6):586-589 (Pubitemid 19145776)
99. Grant M, Alturaihi H, Jaquet P, et al. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 2008;22:2278-2292
100. Haraguchi K, Ohtaka M, Takazawa K, et al. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly. Endocr J 1995;42(2):295-300
101. Wahid ST, Marbach P, Stolz B, et al. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 2002;146(3):295-302 (Pubitemid 34257638)
102. Ronchi CL, Rizzo E, Lania AG, et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 2008;158(1):19-25 (Pubitemid 351211036)
103. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006;91(6):2112-2118 (Pubitemid 43854991)
104. Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006;64(3):342-351
105. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66(6):859-868 (Pubitemid 47024274)
106. Losa M, Mortini P, Urbaz L, et al. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 2006;104(6):899-906 (Pubitemid 43824739)
107. Bruns C, Lewis I, Briner U, et al. SOM 230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;1465:707-716 (Pubitemid 34552506)
108. Van Der HJ, De Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89(2):638-645 (Pubitemid 38269871)
109. Rocheville M, Lange DC, Kumar U, et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000;288(5463):154-157 (Pubitemid 30203051)
110. Jaquet P, Gunz G, Saveanu A, et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005;28(Suppl 11):21-27